News & Updates
Filter by Specialty:
Novel drug promising for paediatric Tourette syndrome
The experimental drug ecopipam helps minimize motor and phonic tics in children and adolescents with Tourette syndrome, in addition to being safe and well tolerated, according to the results of a phase 2b trial presented at the 2022 American Academy of Neurology’s Annual Meeting (AAN 2022).
Novel drug promising for paediatric Tourette syndrome
26 Apr 2022
Ofatumumab boasts long-term safety in relapsing multiple sclerosis
Treatment with ofatumumab in the long term (approximately 3.5 years) among patients with relapsing multiple sclerosis (MS) is well-tolerated, with no new safety risks found, according to the results of ALITHIOS, presented at the 2022 Annual Meeting of the American Academy of Neurology.
Ofatumumab boasts long-term safety in relapsing multiple sclerosis
26 Apr 2022
Biofeedback with VR cuts acute medication use in chronic migraine
The use of a combined biofeedback-virtual reality (VR) device as an add-on to standard medical care leads to a significant reduction in the need for acute medication in patients with chronic migraine, according to a study reported at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).
Biofeedback with VR cuts acute medication use in chronic migraine
26 Apr 2022
Do chronic pain and headache induce cognitive decline in older adults?
A recent systematic review has found studies that report cognitive decline among older patients with chronic pain and headache, but some papers have not seen such association.
Do chronic pain and headache induce cognitive decline in older adults?
25 Apr 2022
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
20 Apr 2022
AF affects one-third of patients after cryptogenic stroke, TIA
Almost 30 percent of patients who experience a cryptogenic stroke or transient ischaemic attack (TIA) go on to develop atrial fibrillation (AF), most of them asymptomatic, according to results of the NOR-FIB* study presented at EHRA 2022.